



# Characterization of Differentially Abundant Proteins Among *Leishmania (Viannia) braziliensis* Strains Isolated From Atypical or Typical Lesions

Bárbara B. Esteves<sup>1</sup>, Marcella N. Melo-Braga<sup>2</sup>, Vladimir Gorshkov<sup>3</sup>, Thiago Verano-Braga<sup>4</sup>, Martin R. Larsen<sup>3</sup>, Célia M. F. Gontijo<sup>5</sup>, Patricia F. Quaresma<sup>6</sup> and Helida M. Andrade<sup>1\*</sup>

<sup>1</sup> Laboratório de Leishmanioses, Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, <sup>2</sup> Laboratório de Biologia Sintética e Biomiméticos, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, <sup>3</sup> Departament of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark, <sup>4</sup> Núcleo de Proteômica Funcional, Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, <sup>6</sup> Study Group in Leishmaniosis, Instituto René Rachou (IRR) –Fundação Oswaldo Cruz (FIOCRUZ/MG) Belo Horizonte, Belo Horizonte, Brazil, <sup>6</sup> Departamento de Microbiologia Imunologia e Parasitologia, Universidade Federal de Santa Catarina, Florianópolis, Brazil

Leishmania (Viannia) braziliensis is the main etiological agent of cutaneous and mucocutaneous leishmaniasis in Latin America. Non-ulcerated atypical tegumentary leishmaniasis cases caused by L. braziliensis have been reported in several regions of the American continent, including the Xacriabá indigenous reserve in São João das Missões/Minas Gerais, Brazil. Parasites isolated from these atypical clinical lesions are resistant to antimony-based therapeutics. In the present study, proteins displaying differential abundance in two strains of L. braziliensis isolated from patients with atypical lesions compared with four strains isolated from patients with typical lesions were identified using a quantitative proteomics approach based on tandem mass tag labeling (TMT) and mass spectrometry. A total of 532 (P<0.05) differentially abundant proteins were identified (298 upregulated and 234 downregulated) in strains from atypical lesions compared to strains from typical lesions. Prominent positively regulated proteins in atypical strains included those that may confer greater survival inside macrophages, proteins related to antimony resistance, and proteins associated with higher peroxidase activity. Additionally, we identified proteins showing potential as new drug and vaccine targets. Our findings contribute to the characterization of these intriguing L. braziliensis strains and provide a novel perspective on Atypical Cutaneous Leishmaniasis (ACL) cases that have been associated with therapeutic failures.

Keywords: Leishmania braziliensis, atypical wounds, proteome, abundance, TMT, antimony resistance

#### **OPEN ACCESS**

#### Edited by:

Juliana Perrone Bezerra De Menezes, Gonçalo Moniz Institute (IGM), Brazil

#### Reviewed by:

Patricia Cuervo, Oswaldo Cruz Foundation (Fiocruz), Brazil Celio Geraldo Freire-de-Lima, Federal University of Rio de Janeiro, Brazil

> \*Correspondence: Helida M. Andrade helidandrade@gmail.com

#### Specialty section:

This article was submitted to Parasite and Host, a section of the journal Frontiers in Cellular and Infection Microbiology

Received: 29 November 2021 Accepted: 14 January 2022 Published: 15 February 2022

#### Citation:

Esteves BB, Melo-Braga MN, Gorshkov V, Verano-Braga T, Larsen MR, Gontijo CMF, Quaresma PF and Andrade HM (2022) Characterization of Differentially Abundant Proteins Among Leishmania (Viannia) braziliensis Strains Isolated From Atypical or Typical Lesions. Front. Cell. Infect. Microbiol. 12:824968. doi: 10.3389/fcimb.2022.824968

1

# **1 INTRODUCTION**

In different parts of the world, authors have referred to Atypical Cutaneous Leishmaniasis (ACL) cases as sporotrichoid, reported in Pakistan, but no Leishmania species was identified (Iftikhar et al., 2003), erysipeloid, reported in Anatolia, Turkey, also unidentified species of Leishmania (Karincaoglu et al., 2004), recidiva cutis, caused by L. panamensis (Calvopina et al., 2005) or zosteriform, reported in Iran (Omidian and Mapar, 2006). On the other hand, Leishmania (Viannia) braziliensis is an important Leishmania species that circulates in several North and South American countries. This species can cause a wide spectrum of clinical manifestations ranging from single and typical lesions with a granular background and raised edges, known as cutaneous leishmaniasis (CL), to the involvement of nasal and oral mucous membranes, also known as the cutaneousmucosal or mucosal form (Lainson and Shaw, 1998). The spectrum of injuries caused by L. braziliensis also includes reports of atypical cutaneous leishmaniasis (ACL), with characteristics such as papules, verrucous and keloid lesions, and crusted and ulcerated plaques, distinct from those presented by common injuries (Baptista et al., 2009; Guimarães et al., 2009; Quaresma et al., 2018). In an area hyperendemic for L. braziliensis transmission in northeastern Brazil, ACL accounted for 1.9% of all tegumentary leishmaniasis cases (Guimarães et al., 2009). Possible causes associated with ACL are host immune status (pregnancy, co-morbidities, immunosuppression (Iftikhar et al., 2003; Omidian and Mapar, 2006), environmental factors, and strain of the parasite (Guimarães et al., 2016). However, the majority of such patients do not present with clinical co-morbidities or HIV infection and are not using immunosuppressive drugs (Da-Cruz et al., 1999). Furthermore, L. braziliensis is characterized by variable infectivity, virulence, and response to antileishmanial therapy (Rego et al., 2018; Patino et al., 2019a); thus, there is no consensus on the factors involved in cases of ACL, although these data seem to suggest that parasite factors may be more determinant.

In Brazil, ACL cases have been reported in the states of Rio de Janeiro (Baptista et al., 2009), Bahia (Guimarães et al., 2009), and Minas Gerais (Quaresma et al., 2018) and are associated with genetic variations of the parasite and lower response to treatment with antimonials. In the state of Minas Gerais (MG), ACL cases were observed in patients from the Xacriabá indigenous reserve located in the municipality of São João das Missões. The reserve is predominantly composed of Brazilian savannah (cerrado) vegetation, and Lutzomyia intermedia is the main vector of L. (V.) braziliensis in this region (Rego et al., 2018). In patients from Xacriabá, cytokine/chemokine expression in skin biopsies is associated with the time of lesions, but not with the type of injury. Additionally, histopathological analysis of cutaneous tissue samples did not show any differences between patients with different types of lesions (Costa-Silva et al., 2014). However, genetic polymorphisms are correlated with typical or atypical clinical manifestations (Quaresma et al., 2018). A large number of therapeutic failures were observed in patients with atypical

lesions, and an *in vitro* study of antileishmanial drug susceptibility reported that strains from atypical manifestations are more resistant to Glucantime, the antileishmanial treatment recommended by the WHO (Rugani et al., 2019). Moreover, atypical manifestations have been demonstrated to be related to therapeutic failure (Guimaraes et al., 2016).

Proteomic analysis is a fundamental tool for understanding physiological processes and for studying the relationships between the genotype and the phenotype. Quantitative proteomics have been used for several Leishmania species in studies aiming at different aspects of biology, such as identifying protein modification during differentiation in L. donovani (Pawar et al., 2020), identification of differentially abundant proteins probably involved in the virulence of amastigote and promastigote forms of L. infantum (Fialho-Junior et al., 2021), and analysis of in vitro and in vivo models of cutaneous leishmaniasis using L. amazonensis and L. major (Negrão et al., 2019). Here, we performed a proteomic analysis using TMT labeling followed by mass spectrometry (MS) to identify differentially abundant proteins in L. braziliensis promastigotes that cause typical and atypical lesions. Our findings contribute to the characterization of the selected L. braziliensis strains, highlighting the importance of conducting new studies to elucidate the factors involved in the wide diversity of clinical manifestations and drug response outcomes in clinical practice.

# **2 MATERIALS AND METHODS**

### **2.1 Ethics Statement**

*Leishmania* field strains were obtained from human patients living in the Xacriabá indigenous community located in São João das Missões municipality, Minas Gerais, Brazil (Quaresma et al., 2018). Samples from other endemic areas were obtained from the outpatient care clinic at Centro de Referência em Leishmanioses – Instituto René Rachou-IRR/FIOCRUZ from 1993 to 1998. All patients involved in this study provided written informed consent, and experimental procedures were approved by the IRR Research Ethics Committee in Human Research, the National Committee for Research Ethics (Comissão Nacional de Ética em Pesquisa – CONEP; process 355/2008), and the National Indian Foundation (Fundação Nacional do Índio – FUNAI; n° 149/CGEP/08).

# 2.2 Parasites

The *L. braziliensis* strains from typical (LbTL) lesions were isolated from patients from Belo Horizonte, MG, Brazil, identified as MHOM/BR/95/RR051 and BH17 and from São João das Missões, MG, Brazil identified as MHOM/BR/08/426 and MHOM/BR/09/346. The strains from atypical lesions (LbAL) were isolated from São João das Missões, MG, Brazil, identified as MHOM/BR/08/316 and MHOM/BR/08/340. The clinical features of typical and atypical lesions from which the parasites were isolated and the isolation and confirmation of the species were

performed as described by Quaresma et al. (2018). In summary, the typical lesions were characterized like circular or oval ulcers with an erythematous, infiltrated, firm, reddish and granular base and a well-delimited, elevated border. Atypical lesions were defined by the presence of unusual cutaneous wounds.

The isolation procedures were accomplished added lesion fragments to tubes containing NNN medium (Novy and McNeal, 1903; Nicolle, 1908) enriched with liquid Schneider's medium and incubated at  $25 \pm 1^{\circ}$ C. The cultures were examined weekly and were considered positive when Leishmania promastigotes were observed. The species identification methods performed for characterizing the isolates used in this study was done by the Leishmania Isolation, Culture and Typing Service of the Leishmania Collection of the Oswaldo Cruz Institute (Coleção de Leishmania do Instituto Oswaldo Cruz -CLIOC) according to the protocol described by Cupolillo et al. (1994). We also used hsp70-PCR-RFLP which amplified a 1300bp fragment of the hsp70 gene and subsequently the restriction profiles were obtained from HaeIII digestion of the PCR products. In addition to these methods the sequencing of the 1,300 bp fragment of hsp70 were performed. The combination of identification methods allowed the characterization of parasites as L. braziliensis.

Promastigotes of L. braziliensis were maintained in M199 culture media (SigmaAldrich/Merck) supplemented with 10% fetal bovine serum (ThermoFischer/Gibco), 100 units/mL penicillin (ThermoFischer/Gibco), 100 µg/mL streptomycin (ThermoFischer/Gibco), 12.5 mM glutamine (ThermoFischer/ Gibco), 0.1 M adenine (SigmaAldrich/Merck), 205 µg/mL hemin, and 40 mM HEPES (SigmaAldrich/Merck), pH 7.4 at 26°C. Overall, six isolates were evaluated: four from typical lesions and two from atypical lesions. All strains were cultivated in independent triplicates under identical conditions until the 9th passage, when promastigotes were obtained in the final stage of the stationary growth phase. This phase was established after performing the growth curve for eight consecutive days. During this period, motility and morphological aspects such as cell body and flagellum length were also observed. Thus, promastigotes forms were harvested in the stationary phase (5<sup>th</sup> day) by centrifugation at 3,000 x g for 15 min at 4°C. Cell pellets were washed three times in phosphatebuffered saline (PBS), pH 7.2, and frozen at -80°C until use.

# 2.3 Quantitative Proteomics

### 2.3.1. Protein Extraction and TMT-Labeling

Frozen promastigotes, as described above, (LbAL and LbTL) were lysed for 2 h at 24°C in lysis buffer [8 M urea, 2 M thiourea, 4% CHAPS, 65 mM dithiothreitol (DTT), 1 M Tris, 40 mM protease inhibitor cocktail containing serine protease inhibitors, and cysteine protease inhibitors (Protease Inhibitor Mix; GE Healthcare, USA)] at a density of 500  $\mu$ L per 10° parasites. The cell lysate was passed 10 times through a 26G needle and centrifuged at 20000 × g for 20 min. The supernatant was aliquoted and stored in a freezer at  $-80^{\circ}$ C until use. Protein concentration was determined using a QuantKit 2D (GE Healthcare) according to the manufacturer's recommendations.

Equal amounts of protein (300  $\mu$ g) from each sample were reduced *via* incubation with 50 mM dithiothreitol (DTT) for 1 h at 24°C and subsequently alkylated with 150 mM iodoacetamide (IAA) for 30 min at room temperature in the dark. Before the digestion step, the samples were washed with buffer (6M urea and 50 mM TEAB) to dilute the CHAPS present in the lysis buffer. Protein purification and concentration filters (Micon <sup>®</sup> Ultra-0.5 mL) were used for these washes. Enzymatic digestion was performed using trypsin (Promega, Madison) at a ratio of 1:50 for 16 h at 37°C.

After protein digestion, peptides were labeled with specific isobars from the TMT<sup>®</sup> 10plex Isobaric Mass Tagging Kit (Thermo Fisher Scientific/Pierce Biotechnology, Rockford, USA) following the manufacturer's instructions. Briefly, 15  $\mu$ g of each sample was labelled with 0.266 mg of an isobaric amine-reactive tag (TMT10-126, TMT10-127N, TMT10-127C, TMT10-128N, TMT10-128C, and TMT10-129N). The reaction mixture was incubated for one hour at room temperature for complete labeling. The reaction was quenched by the addition of 5% hydroxylamine, and labelled peptides were combined at a ratio of 1:1:1:1:1:1. The samples were dried using a SpeedVac and stored for further analysis. The preparation process was performed in biological triplicates.

#### 2.3.2 High pH Reversed Phase Pre-Fractionation

Labeled peptide mixtures were dissolved in buffer A (20 mM ammonium formate, pH 9.3) and fractioned using an Acquity UPLC M-Class Peptide CSH C18 column (1.7  $\mu$ m, 300  $\mu$ m x 100 mm) (Waters) on an UltiMate 3000 high-pressure liquid chromatography (HPLC) system (Dionex, Sunnyvale, CA, USA) operating at 5  $\mu$ L/min. Each set was eluted using the following chromatographic gradient expressed as a percentage of solvent B (20% solution A/80%ACN): 2–40% for 27 min, 40–50% in 4 min, 50–70% in 4 min, and 70–95% in 5 min. Each sample was separated into 15 fractions that were further merged into five concatenated fractions, and dried using a SpeedVac prior to MS analysis.

### 2.3.3 LC-MS/MS

Pre-fractionated TMT-labeled peptides were resuspended in solvent A (0.1% (v/v) formic acid) and subsequently injected into an EASY-nLC system (Thermo) with a two-column system setup. The pre-column was 3 cm in length and 100  $\mu$ m in inner diameter, and it was packed with 5 µm (particle size) Reprosil-Pur C18-AQ resin (Dr. Maisch GmbH). An analytical column (17 cm  $\times$  75 µm) was packed with a 3 µm Reprosil-Pur C18-AQ resin (Dr. Maisch GmbH). Peptides from each fraction were eluted for 68 min using the following gradient expressed as a percentage of solution B (95% acetonitrile/0.1% formic acid): 2-5% in 1 min, 5-25% in 50 min, 25-40% in 10 min, 40-95% in 1 min, 95% in 5 min and 95-2% in 1 min, at a constant flow of 300 nL/min. The Q Exactive HF-X hybrid quadrupole-Orbitrap mass spectrometer (Thermo) was operated in positive mode using data-dependent acquisition (DDA) (Top 20). Peptide ions were resolved in the Orbitrap (MS), in the range of 350 to 1500 m/z with a resolution of 120,000 FWHM (AGC target 3e6 or

maximum injection time of 50ms). At each MS, the 20 most intense ions (Top 20), with the minimum AGC target 1e3, were selected in the quadrupole, using an isolation window equal to 0.7 m/z. These ions were selected for fragmentation (MS2) by higher-energy collision dissociation (HCD), with a normalized collision energy of 33%. The originating fragments were resolved in Orbitrap with a resolution of 45,000 FWHM (AGC target 1e5 or maximum injection time of 60 ms) and included in a dynamic exclusion list for 30 s.

#### 2.3.4 Data Analysis

Raw data were analyzed using the Proteome Discoverer 2.1 software. The database search was performed by the SEQUEST using the *Leishmania braziliensis* NCBI database (25,611 sequences). Database search parameters included: i) maximum of two trypsin missing cleavages, ii) carbamidomethylation of cysteine as a fixed modification, iii) oxidation of methionine, N-terminal acetylation of protein, and TMT 6plex (lysine and N-terminal peptide) as variable modifications, iv) precursor and fragment mass tolerance of 10 ppm and 0.02 Da, respectively; v) 1% false discovery rate (FDR); and vi) unique peptides plus razor ones were grouped into the respective proteins. Only master proteins with a 1% FDR were considered for the analysis.

Before statistical analyses, we normalized the log2 transformed ion reporter abundance using the "control" sample (pool of all analyzed samples) for all three datasets. Subsequently, data were normalized by subtracting the median of each group using the Perseus program (https://maxquant.net/ perseus). After combining the three sets, we subtracted the average over all conditions (biological/technical) for each protein. Proteins significantly regulated between LbAL and LbTL conditions were determined by the one-way ANOVA statistical test (P< 0.05) plus log2 fold change of 0.584, using DanteR software (Polpitiya et al., 2008).

The differentially abundant proteins were functionally categorized through annotations of biological processes (BP) and molecular functions (MF) cataloged according to the Gene Ontology (GO) consortium. This set of genomic data was analyzed using the bioinformatics platform TriTrypDB release 40 (http://tritrypdb.org/tritrypdb/). For each category, Fischer's exact test was used to test the enrichment of selected proteins against all proteins identified in the study. A false discovery rate (FDR) and an adjusted P < 0.05 were set as thresholds to define the significance of the functional enrichment.

To evaluate the potential relationship among these proteins using enriched GO categories, we predicted the protein-protein interaction networks associated with the whole proteome of the organism. For this prediction analysis, we used the STRING 10.5 database with a cut-off value of 0.4 considered to be of medium confidence. This database provides a network of predicted interactions or interactions already described in the literature between proteins or between genes (protein-protein interaction networks, http://string-db.org). Finally, the KEGG (Kyoto Encyclopedia of Genes and Genomes) database was used *via* the metabolic pathways enrichment tool (TritrypDB bioinformatics platform) to analyze the pathways of the identified differentially abundant proteins and to understand their biological significance.

#### 2.3.5 Data Availability Statement

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium *via* the PRIDE partner repository with the dataset identifier PXD029995.

# 2.4 Validation Proteomic Data

#### 2.4.1 Peroxidase Activity

Peroxidase activity was measured using  $10^8$  promastigotes from each strain in the LbTL and LbAT groups. Promastigotes were lysed by gentle shaking in 50 µL of 0.1% Triton X-100 for 30 min at room temperature. Next, 50 µM H<sub>2</sub>O<sub>2</sub> (final concentration) was added, followed by incubation at 37°C for 30 min. The reaction was stopped by adding 0.75 mL of trichloroacetic acid solution (8% v/v), and the precipitate was removed by centrifugation. To the supernatant, 0.2 mL of 10 mM ferrous ammonium sulphate and 0.1 mL of 2.5 M potassium thiocyanate were added, and the remaining amount of H<sub>2</sub>O<sub>2</sub> was determined spectrophotometrically (480 nm) by calibration against a standard curve with known concentrations of H<sub>2</sub>O<sub>2</sub> (Jiang et al., 2005).

Statistical analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA). Data are presented as means of the group. Comparisons between different groups were made using one-way ANOVA followed by Bonferroni's test, and statistical significance was set at P< 0.05.

# **3 RESULTS**

# **3.1 Identification and Relative Abundance of Proteins From Atypical and Typical Strains**

We performed an isobaric tagging and high-resolution mass spectrometry strategy to compare the proteome of L. braziliensis strains that cause atypical lesions (LbAL, n=2) and L. braziliensis strains that cause typical lesions (LbTL, n=4). Each strain was analyzed in triplicate, resulting in triplicates of independent experiments. This approach enabled the identification of 4,048 non-redundant proteins (Supplementary Table S1), of which 2,229 proteins were present in all three independent runs (Figure 1A). To assess the differentially abundant proteins, we compared the relative abundance values of the identified proteins in LbAL versus LbTL strains. Our results showed that the abundance of 298 and 234 proteins significantly increased and decreased in LbAL strains, respectively, compared to LbTL strains (Figure 1B). However, when we considered only proteins identified in at least two of the three runs, 254 (Supplementary Table S2) and 196 (Supplementary Table S3) proteins were upregulated and downregulated at LbAL versus LbTL (Figures 1C, D).



**3.2 Functional Analysis** Gene Ontology (GO) data were used to glean insights into the differences between atypical and typical *L. braziliesnis* strains. The GO enrichment of regulated proteins associated GO term to 37 proteins with increased abundance and 16 with decreased abundance in atypical strains compared to typical strains. These proteins were categorized into functional groups (**Figure 2**).

Regarding Molecular Function (MF), the category Oxidoreductase activity, acting on a sulfur group of donors (P=4.11e-4) followed by enzyme inhibitor activity (P=3.33e-4) were significantly enriched in the group of upregulated proteins. These groups are represented mainly by the following proteins: trypanothione reductase, peptide methionine sulfoxide reductaselike, and ecotin. In the group of downregulated proteins, we observed that oxidoreductase activity, acting on CH-OH group of donors (6.27e-4), protein serine/threonine kinase activity (P=6.45e-4), oxidoreductase activity (P=7.30e-4), and oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor (P=1.03e-3) were among the significant categories. These groups are represented mainly by the following proteins: malate dehydrogenase and choline dehydrogenase (Figure 2A and Table 1).

The biological process (BP) with statistical significance among proteins with increased abundance in atypical strains compared to typical strains were cellular nitrogen compound biosynthetic process (P=4.68e-5 with 27 proteins), peptide metabolic process (P=1.49e-4 with 20 proteins), and cellular amide metabolic process (P=2.42e-4 with 20 proteins). These groups are mainly represented by ribosomal proteins. In contrast, no significantly enriched category was found for downregulated proteins (**Figure 2B** and **Table 2**)

# **3.3 Prediction of Protein-Protein** Interaction (PPI)

To identify possible interactions between the identified proteins, a prediction analysis of protein interactions was performed using String 10.5. The network obtained was composed of 21 upregulated and 9 downregulated proteins. The obtained networks were later edited in Cytoscape 3.4.0, to assign colors to positive and negative adjustment values. The positively



regulated proteins interacted with each other, mainly represented by reductase proteins, and similarly, the negatively regulated proteins interacted with each other, mainly represented by dehydrogenases proteins. Moreover, it is possible to observe the interactions among ribosomal proteins, all of which are positively regulated in strains isolated from atypical lesions compared to strains isolated from typical lesions (**Figure 3**).

# **3.4 Analysis of Enrichment of Metabolic Pathways**

The KEGG tool was used to identify the most relevant pathways associated with regulated proteins in the promastigote forms of Leishmania, causing atypical lesions. Regarding positively regulated proteins, the analysis showed the enrichment of five pathways: cysteine and methionine metabolism (P=1.58e-4, with 10 proteins), glutathione metabolism (P=5.96e-3, with 6 proteins), phenylalanine metabolism (P=6.79e-3, with 6 proteins), polyketide sugar unit biosynthesis (P=8.46e-3, with 6 proteins), and tyrosine metabolism (P=9.85e-3, with 9 proteins). In contrast, negatively regulated proteins participated in six pathways: carbon fixation pathways in prokaryotes (P=1.37e-4, with 8 proteins); valine, leucine, and isoleucine degradation (P=4.60e-3, with 5 proteins); benzoate degradation (P=7.99e-3, with 5 proteins); glyoxylate and dicarboxylate metabolism (p=8.69e-3, with 5 proteins); geraniol degradation (P=9.85e-3, with 3 proteins); and one carbon pool by folate (P= 9.85e-3, with 3 proteins) (Figure 4). Proteins belonging to each pathway are listed in Table 3, where it can be observed that each protein participates in more than one pathway, except in the case of glutathione metabolism. To verify the interactions between the identified proteins belonging to the enriched pathways, prediction analysis of protein interactions was performed

(Figure 5), highlighting that the dehydrogenases were negatively regulated and interacted with each other, and trypanothione and tryparedoxin were positively regulated and interacted with each other.

# **3.5 Peroxidase Activity**

Glutathione (GSH) plays a central role in cell defense against oxidative stress. In trypanosomatides, the removal of peroxides is performed by tryparedoxin peroxidase (Collotti et al., 2013). Tryparedoxin peroxidase was found among the upregulated proteins belonging to the glutathione pathway (ratio LbAL *vs* LbTL = 0.993897). Therefore, the antioxidant capacities of different strains were evaluated. Since after 30 min of exposure to 50  $\mu$ M hydrogen peroxide, protein extracts from strains belonging to the atypical group consumed all H<sub>2</sub>O<sub>2</sub>, the reported value should be interpreted as lower boundary (no standard deviation can be calculated), while those in the typical group consumed an average of 15.7  $\mu$ M of H<sub>2</sub>O<sub>2</sub>. The hydrogen peroxide consumption in the atypical group was 3.01-fold higher than that in the typical group (*P*<0.001; **Figure 6**).

# **4 DISCUSSION**

Determining factors of atypical cutaneous leishmaniasis (ACL) caused frequently by *Leishmania (Viannia) braziliensis* remain unclear. It is possible that these clinical forms are determined by host and parasite factors, as demonstrated for other clinical forms of leishmaniasis. However, histopathological analysis of cutaneous tissue samples and cytokine/chemokine expression in skin biopsies from ACL patients showed no association with the

TABLE 1 | Gene Ontology (GO) enrichment analysis of Molecular Function in differentially regulated proteins in *L. braziliensis* from atypical lesion (LbAL) compared to *L. braziliensis* from typical lesion (LbAL).

TERM	Fold change (P value)	PROTEINS	RATIO (LbAL vs LbTL)
Upregulated proteins			
Oxidoreductase activity, acting on a sulfur group of donors	7.43 (4.11e-4)	trypanothione reductase	2.417
		peptide_methionine sulfoxide reductase-like	1.060
		putative thioredoxin	0.984
		thiol-dependent_reductase_1	0.709
		putative glutaredoxin-like protein	0.649
Enzime inhibitor activity	18.26 (3.33e-4)	ecotin	1.917
		Ecotin-like protein 2	0.797
		Protein phosphatase inhibitor 2 (IPP-2)	0.768
Downregulated proteins			
Oxidoreductase activity. acting on CH-OH group of donors	7.02 (6.27e-4)	mitochondrial malate dehydrogenase	-1.150
		choline dehydrogenase like protein,	-1.062
		glycosomal malate dehydrogenase	-0.944
		dehydrogenase-like protein	-0.888
		putative short chain 3-hydroxyacyl-CoA dehydrogenase	-0.825
Protein serine/threonine kinase activity	9.70 (6.45e-4)	putative target of rapamycin (TOR) kinase 1	-1.744
		putative protein kinase	-1.029
		protein kinase A catalytic subunit isoform 1	-0.765
		protein kinase A catalytic subunit	-0.676
Oxidoreductase activity	2.73 (7.30e-4)	mitochondrial malate dehydrogenase	-1.150
		choline dehydrogenase, like protein	-1.062
		putative short chain dehydrogenase	-1.017
		conserved hypothetical protein (134065654)	-0.978
		glycosomal malate dehydrogenase	-0.944
		putative endoplasmic reticulum oxidoreductin	-0.938
		dehydrogenase-like protein	-0.888
		putative short chain 3-hydroxyacyl-CoA	-0.825
		dehydrogenase	
		fatty acid desaturase	-0.700
		aldehyde dehydrogenase, mitochondrial precursor	-0.696
		conserved hypothetical protein (134063632)	-0.662
		putative C-1-tetrahydrofolate synthase, cytoplasmic	-0.655
Oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor	35.57 (1.03e-3)	putative endoplasmic reticulum oxidoreductin	-0.938
		conserved hypothetical protein (134063632)	-0.662

Proteins sorted by log2-ratio.

type of injury (Costa-Silva et al., 2014). In contrast, the parasite presented genetic polymorphism correlated with atypical clinical manifestations (Quaresma et al., 2018) and was more resistant to N-methylglucamine antimonate (Rugani et al., 2019); clinical cases have been associated with therapeutic failures (Guimarães et al., 2016). Thus, we performed a comparative proteomic analysis to identify differentially abundant proteins among *L.* (*V.) braziliensis* strains isolated from atypical lesions (LbAL) compared to isolates from typical lesions (LbTL). The strains used in the present study were previously characterized for genetic polymorphism, as well as for resistance to N-methylglucamine antimonate; the typical strains are genetically non-polymorphic and sensitive to glucantime, whereas the atypical strains are genetic polymorphic and resistant to N-

methylglucamine antimonate (Rugani et al., 2018; Quaresma et al., 2018).

Since the role of the parasite in a large clinical plasticity of *L. braziliensis* infections is not clear this study aims to contribute to the knowledge about the factors involved in such pleomorphism. We quantified 4,048 proteins, of which 254 and 196 proteins showed increased and decreased abundance, respectively, in atypical strains compared to typical strains. To identify potential factors related to each strain, proteins were categorized into functional groups based onmolecular function (MF) and biological process (BP), followed by prediction analysis of protein interactions (PPI) as well as pathway enrichment analysis using the KEGG tool. The data pointed to upregulated redox activity in atypical strain, among others, the peroxidase activity test validated the findings.

**TABLE 2** Gene Ontology (GO) enrichment analysis of Biological Process in differentially regulated proteins in *L. braziliensis* from atypical lesion (LbAL) compared to *L. braziliensis*. Proteins sorted by log2-ratio.

TERM	Fold change (P value)	PROTEINS	RATIO (LbAL vs LbTL)
Upregulated proteins			
Cellular nitrogen compound biosynthetic process	2.22 (4.68e-5)	putative 60S ribosomal protein L10a	1.807
	(	40S ribosomal protein S24e	1.398
		60S ribosomal protein L32	1.357
		putative DNA-directed RNA polymerase II	1.342
		FtsJ-like methyltransferase	1.287
		DNA primase large subunit	1.237
		Chain B. Dihvdroorotate dehvdrogenase	1.224
		nucleoside diphosphate kinase b	1.072
		putative 60S acidic ribosomal protein	1.048
		putative 40S ribosomal protein S30	1.041
		deoxyribose-phosphate aldolase	0.969
		conserved hypothetical protein	0.954
		kynureninase	0.952
		conserved hypothetical protein	0.891
		60S acidic ribosomal protein P2	0.816
		inosine-quanosine transporter	0.770
		acidic ribosomal P2 beta protein	0.769
		putative methylthioadenosine phosphorylase	0.717
		putative 60S ribosomal protein L13a	0.712
		putative 605 ribosomal protein L 19	0.708
		putative eccended protein 215	0.669
		putative ribosomal protein S7	0.624
		putative asparaginul-tRNA synthetase	0.623
		putative apparaging in a synthetase	0.616
		putative ribosomal protein L27	0.609
		putative ribosomal protein L15	0.601
		putative 60S ribosomal protein L 5	0.601
Pentide metabolic process and	2 47	putative 606 hisosomal protein 10a	1 807
replue metabolic process and	(1 490-4)	putative ous housonal proteinmoa	1.007
Cellular amide metabolic process	2 38	10S ribosomal protein S24e	1 308
	(2.42e-4)		1.000
		60S ribosomal protein L32	1.357
		FtsJ-like_methyltransferase	1.287
		conserved hypothetical protein	1.119
		putative 60S acidic ribosomal protein	1.048
		putative 40S ribosomal protein S30	1.041
		conserved hypothetical protein	0.891
		60S_acidic_ribosomal_protein_P2	0.816
		acidic ribosomal P2 beta protein	0.769
		putative 60S ribosomal protein L13a	0.712
		thiol-dependent_reductase_1	0.709
		putative 60S ribosomal protein L19	0.708
		putative arginyl-tRNA synthetase	0.669
		putative ribosomal protein S7	0.624
		putative asparaginyl-tRNA synthetase	0.623
		putative ribosomal protein I35a	0.616
		putative ribosomal protein L27	0.609
		putative ribosomal protein L15	0.601
		putative 60S ribosomal protein L5	0.601

Inside the mammalian host, *Leishmania* lives in the lethal enzymatic environment of macrophage cells, where they deal with the macrophage-generated oxidative stress to survive. Their survival is attributed to a unique redox metabolism with which the parasite has evolved. In the present study, the oxidoreductase activity of proteins that act on sulfur group donors was upregulated in atypical strains compared to typical strains. Our results show that in this process, five proteins were increased, represented mainly by trypanothione reductase (TR), with a higher positive ratio (2.42) followed by peptide methionine sulfoxide reductase-like (Msr) (ratio =1.06). Both TR and Msr are proteins that catalyze reduction reactions and contribute to the antioxidant defenses of these parasites. TR is an enzyme found in trypanosomatides, equivalent to glutathione reductase. This enzyme is a homodimer NADPH-dependent flavoprotein oxidoreductase that participates in central thiol-disulfide exchange reactions as an electron donor in different metabolic pathways, from the synthesis of DNA precursors to oxidant



detoxification (Mittal et al., 2005; Colotti et al., 2013). TR neutralizes hydrogen peroxide produced by macrophages during infection through the tryparedoxin/tryparedoxin peroxidase I (TXN/TXNPx) system (Colotti et al., 2013). Therefore, TR inhibition increases the intracellular levels of reactive oxygen species that are lethal to the parasite. Similarly, Msr is a protein that catalyzes the reduction reaction, in this case, reducing oxidized methionine residues. Rodríguez-Veja et al. (2021) showed that strains of L. braziliensis related to disseminated leishmaniasis (DL) might also have a greater resistance to oxidative stress, mediated by the increased abundance of trypanothione reductase, and thioredoxin-like fold domain containing protein. Consistently, disruption of the trypanothione reductase gene decreases the Leishmania infectivity and its ability to survive within the macrophage. Thus, our results indicate that the parasites that cause atypical

lesions present increased abundance of some proteins related to redox homeostasis, which may confer greater survival inside macrophages.

Pentavalent antimony-containing compounds (sodium stibogluconate Pentostam<sup>®</sup> and N-methyl-glucamine Glucantime<sup>®</sup>) have been the first-line drugs for the treatment of all clinical forms of leishmaniasis since 1940 (Davidson, 1999), and as no human vaccine is in clinical use, chemotherapy relying on pentavalent antimonial still is the most important control for leishmaniasis. The mechanism of action of antimony has not been fully elucidated; however, SbIII (stibogluconate) is purported to generate disturbances in the thiol redox potential of the parasite by inducing the efflux of intracellular thiols and by inhibiting trypanothione reductase, resulting in cell death by oxidative stress (Wyllie et al., 2004). The antimony susceptibility test (EC 50 assay) revealed that L. braziliensis lines



overexpressing cytosolic tryparedoxin peroxidase (cTXNPx) had a 2-fold increase in resistance to SbIII compared to the untransfected parental line. Furthermore, these clones were more tolerant to exogenous H2O2 than the untransfected parental line (Moreira and Murta, 2016). Similarly, overexpression of nucleoside diphosphate kinase b and elongation factor 2 results in an increase in SbIII resistance in L. braziliensis (Andrade and Murta, 2014). Corroborating these literature data, the results of the present work, in which we used naturally-occurring antimony-resistant strains that cause AL, showed that these strains present upregulated reductase proteins (trypanothione reductase, thioredoxin, peptide methionine sulfoxide reductase-like, thiol-dependent reductase 1, nucleoside diphosphate kinase b, deoxyribose phosphate aldolase, and methyltioadenosine phosphorilase, which interact with each other (Figure 3). Some of these proteins also participate in glutathione metabolism (one of the enrichment pathways shown by the KEGG tool). Atypical strains showed 3.01-fold higher peroxidase activity than typical ones (P<0.001, Figure 5). As already mentioned, the atypical strains used in present study were previously characterized as resistant to Nmethylglucamine antimonate (Rugani et al., 2018) then, we believe that, collectively, it was possible to identify the proteins related to antimony resistance and prove the greater peroxidase activity in strains of the typical group. These data shed new light on ACL cases that have been associated with therapeutic failures.

Therefore, regarding MF, we observed enrichment of "Enzyme inhibitor activity" as upregulated terms in atypical strains, including the proteins ecotin, ecotin-like, and protein phosphatase inhibitor 2 (IPP-2). Ecotin is a serine protease inhibitor produced by hundreds of microbial species, including pathogens such as *Leishmania* spp. Parasites encode inhibitors of

serine protease (ISP), which inhibits serine proteases of the immune response system and manipulates the host physiological processes to ensure their survival. In L. major, ISP targets host serine peptidases and influences the early stages of infection of the mammalian host (Eschenlauer et al., 2009). Alam et al. (2016) identified, purified, and characterized an endogenous ISP from an Indian strain of L. donovani, which causes fatal visceral leishmaniasis, and these inhibitors show varying and entirely contrasting efficacies toward serine proteases of its own as well as of higher organisms. To that authors, this indicates that it accelerates disease progression and drives parasite survival by inhibiting the activities of host serine proteases. Subsequently, it was demonstrated that ecotin blocks activation of the complement lectin pathway by inhibiting its key activator enzymes, MASP-1 and MASP-2. Furthermore, by inhibiting MASP-3, ecotin also disrupts the fundamental link between lectin and alternative pathways. Thus, ecotin is a potent, versatile self-defense tool that blocks multiple antimicrobial activities in the serum. These findings suggest that ecotin may be a relevant antimicrobial drug target (Nagy et al., 2019). Thus, our data suggest that ecotin could be a new drug target to be tested in strains that are resistant to antimony, as already mentioned. Our data also showed positive regulation of protein phosphatase inhibitor 2 (IPP-2). Protein phosphorylation and dephosphorylation are well recognized as important processes that regulate multiple physiological mechanisms. To date, there are no reports on IPP-2 from Leishmania; nevertheless, it is a protein involved in the regulation of phosphoproteins and regulation of signal transduction that is able to impede the activity of a protein phosphatases, enzymes that hydrolyzes phosphate groups from phosphorylated proteins. Upregulation of phosphatase inhibitors consequently allows higher activity of TABLE 3 | KEGG enriched pathways of differentially regulated proteins in L. braziliensis from atypical lesion (LbAL) compared to L. braziliensis from typical lesion (LbTL).

UPFECULATED <ul> <li>Optimize and methodnine metabolism</li> <li>Plat-like, methytransferase</li> <li>1.2671051</li> <li>putative stark 24methytransferase</li> <li>0.268240</li> <li>Conserved Hypothetical protein (15406340)</li> <li>0.6683841</li> <li>putative appartate aminotransferase</li> <li>0.679261</li> <li>putative appartate aminotransferase</li> <li>0.6792761</li> <li>putative angine N-methytransferase, type III</li> <li>0.6618816</li> <li>putative appartate aminotransferase</li> <li>0.6618816</li> <li>putative appartate aminotransferase</li> <li>0.6618816</li> <li>putative appartate aminotransferase</li> <li>0.6618916</li> <li>putative appartate aminotransferase</li> <li>0.6618916</li> <li>putative appartate aminotransferase</li> <li>putative arginite N-methytransferase</li> <li>putative arginite N-methytramsferase</li> <li>putative arginite N-methytra</li></ul>	PATHWAY	PROTEINS	RATIO(LbAL vs LbTL)
Cysteine and methionine metabolism platiele stymine - hydroxystee (1-49615) Pick-like, enchtyftransferase (1-249706) putative sterd 24-c-methyftransferase (1-249706) putative stard 24-c-methyftransferase (1-249706) putative stard 24-c-methyftransferase (1-249706) putative sapartate amhotransferase (1-249706) putative sapartate amhotransferase (1-249706) putative sapartate amhotransferase (1-249706) putative sapartate amhotransferase (1-249707) putative sapartate amhotransferase (1-249707) putative sapartate amhotransferase (1-249707) putative sapartate amhotransferase (1-249707) putative arginine N-methyftransferase (1-249707)	UPREGULATED		
Pis-Jibs_methyltransforase     1.25702       putative ster/24methyltransforase     0.814614       putative ster/24methyltransforase     0.77708       putative apartate aminotransforase     0.83861       putative apartate aminotransforase     0.838621       putative apartate aminotransforase     0.838621       putative apartate aminotransforase     0.838621       putative apartate aminotransforase     0.838621       putative agrine N-methyltransforase, type III     0.816816       putative agrine N-methyltransforase, type III     0.816816       putative agrine N-methyltransforase, type III     0.816816       putative agrine N-methyltransforase     0.83697       putative agrine N-methyltransforase     0.83697       putative typerotion provides     0.83691       putative typerotion provides	Cysteine and methionine metabolism	putative thymine-7-hydroxylase	1.456151
putative sterol 24methylicandresae         0.814614           putative sapratio aminotandresae         0.6717088           putative sapratio aminotandresae         0.679376           putative sapratio aminotandresae         0.6879376           putative sapratio aminotandresae         0.6879376           putative sapratio aminotandresae         0.6879376           putative aninotandresae         0.6879376           putative apartate aminotandresae         0.6879376           putative		FtsJ-like_methyltransferase	1.287025
putative methylikinaderosine pitosphoylase         0.71708           conserved hypothetical probein (154065540)         0.6573976           putative aspartate aminotransferase         0.6573976           putative angine in Amethylikanaterase, type III         0.816916           putative angine in Amethylikanaterase, type III         0.816916           putative angine in Amethylikanaterase, type III         0.816916           putative materia dividrogenase         0.426721           putative materia dividrogenase         0.436721           putative materia dividrogenase         0.436721           putative sparanoficene synthesia         0.436721           putative sparanoficene synthesia         0.436721           Phanylakinine metabolism         Ful-kike, methylamasferase         0.436721           putative stord 24-c-methylamasferase         0.827221         0.827821           putative stord 24-c-methylamasferase         0.827821         0.827821           putative stord 24-c-methylamasferase         0.827821         0.827821           putative stord 2		putative sterol 24-c-methyltransferase	0.814614
conserved hypothetical protein (194063540)         0.88034           public aspartal a minitoransforase         0.680347           public branched-chan armip add armitoransforase.         0.680347           public branched-chan armip add armitoransforase.         0.680347           public mainotransforase.         0.680347           public mainotransforase.         0.680347           public mainotransforase.         0.680347           intermediation protein.         0.760704           hypothetical protein.         0.760704           public transform.         0.760704		putative methylthioadenosine phosphorylase	0.717098
putative aspartse aminodramsferase         0.673376           putative saminodramsferase         0.683421           Vorsien aminotramsferase         0.683421           putative angine N-methyltransferase, type III         0.661616           putative mailse durydrogenase         0.486371           Optimities induction (\$22504782)         1.724753           Optimities induction (\$22504782)         0.866871           Inductive induction (\$22504782)         0.866871           Propriotentic induction (\$22504782)         0.866871           Inductive induction (\$20504782)         0.866871           Propriotentic induction (\$20504782)         0.866871           Propriotentic induction (\$20504782)         0.868971           Propriotentic induction (\$20504782)         0.869721           Propriotentic induction (\$20504782)         0.869721           Propriotentic induction (\$20504782)         0.869721           Propriotentic induction (\$20504782)         0.869721           Propriotentic induction (\$205340)         0.897721           Propriotentic induction (\$205340)         0.897721           Propriotentic induction (\$205340)         0.897721           Propriotentic induction (\$2053540)         0.897721           Propriotentic induction propriotentinduction (\$2053540)         0.89781      <		conserved hypothetical protein (134063540)	0.686384
putative branched-chain arrito acid arritotansferase         0.829/21           Working and interferase         0.829/21           putative arritine N-methyltransferase, type III         0.8169/16           putative arritine N-methyltransferase, type III         0.8169/16           Statistica Protein, urknown function (\$22504762)         1.724763           typeradoxin, perovidase         0.808987           putative typeradoxin, perovidase         0.808987           putative typeradoxin, perovidase         0.808987           putative typeradoxin, perovidase         0.80897           putative typeradoxin, perovidase         0.809781           putative saparitare aninotransferase         0.809781           potative saparitare aninotransferase         0.809781           putative saparitare aninotransferase         0.809781           putative saparitare aninotransferase         0.809781           putative saparitare aninotransferase         0.809781           putative saparitare aninotransferase         0.809		putative aspartate aminotransferase	0.679376
Spread         Quitable maintoransferase         Quitable         Quitable maintoransferase         Quitable           Guitable metabolism         Uparatorione reductoses         Quitable		putative branched-chain amino acid aminotransferase	0.639421
Guidatione metabolism putative arginine N-methytransferase, type III 0.616916 putative malate diving operatione (322504782) 1.724733 typaretoine, reductase 1.0293897 typaretoine, reductase 1.0293897 tip/depondent_reductase_1.02703709 putative typaretoine (322504782) 0.293897 tip/depondent_reductase_1.02703709 putative store 347-000000000000000000000000000000000000		tyrosine aminotransferase	0.627521
Cluidatione metabolism updative metabolism trust of 247349 EQuidatione metabolism trust of 247349 Physiotelical protein, universen function (322504782) (1724753) (172		putative arginine N-methyltransferase, type III	0.616916
Glutathione metabolism trypanothione reductase 2.417849 hypothetical profesi ,uknown function (822504762) 1.724753 typarotione, peroxidese 0.995887 tinic/dependert_reductase_1 0.0795769 putative trypanothione synthetase 0.0899899 putative typanothione synthetase 0.0897899 putative typanothione synthetase 0.0897899 putative typanothione synthetase 0.0897891 putative typanothione synthetase 0.0897891 putative typanothione synthetase 0.0877871 conserved hypothetical protein (134063540) 0.068834 putative taminotransferase 0.0877871 prosine aminotransferase 0.0877871 prosine aminotransferase 0.0877871 prosine aminotransferase 0.08782 putative tampotentifical protein (134063540) 0.068834 putative tampotentifical protein (134063540) 0.068834 putative tampotentifical synthetase 0.08782 putative tampotentifical synthese 0.08782 putative tampotent (134063540) 0.068838 tyrosine aminotransferase 0.05782 putative tampotent (134063540) 0.068938 putative tampotent (134063540) 0.068938 putative tampotent (134063540) 0.06893 putative tampotentificate store 0.061956 putative tampotentificate store 0.0619		putative malate dehydrogenase	0.585591
hypothetical protein, unknown function (322504762) 1.724783 thypothetical protein (14005762) 0.0369897 thick-dependent, reductase_1 0.0708709 putative ditureatorine synthetiase 1.00708709 putative ditureatorine synthetiase 1.00708709 putative ditureatorine synthetiase 1.027072 putative ditureatorine for sonthetical protein (130063540) 0.0588311 Proyvetide sugar unit biosynthesis Polyvetide polytonetical protein (134063540) Down Headure Angel A	Glutathione metabolism	trypanothione reductase	2.417349
thybersdown_peroxidase         0.49849/           Hind-dependent_relutates_1         0.708709           putative trypanchione synthetase         0.689999           putative trypanchione synthetase         0.689999           putative trypanchione synthetase         0.814614           conserved hypothetical protein (134063540)         0.688334           putative storal 24-o-methyttransferase         0.679376           tyrosine aminotransferase         0.62721           conserved hypothetical protein (134063540)         0.68633           tyrosine aminotransferase         0.81461           conserved hypothetical protein (134063540)         0.66633           tyrosine aminotransferase         0.81461           conserved hypothetical protein (134063540)         0.66633           tyrosine aminotransferase         0.81461           conserved hypothetical protein (134063540)         0.66638           tyrosine minotransferase         0.81461           putative arginine N-methyttransferase         0.81461           tyrosine minotransferase         0.81461           putative arginine N-methyttransferase         0.81461           putative arginine N-methyttransferase         0.81126           putative arginine N-methyttransferase         0.61682           putative arginine N-methyt		hypothetical protein, unknown function (322504762)	1.724753
plantaria         0.0781/19           plantaria         0.0781/19           plantaria         0.0781/19           plantaria         0.0481922           Phenylalanine metabolism         F132102           plantaria         1.327025           putative starol 24-o-methyltransferase         0.868384           postaria         0.679376           prosine aminotransferase         0.679376           conserved hypothetical protein (134063540)         0.698311           Polyleticle sugar unit biosynthesis         F132-like, methyltransferase         0.81461           conserved hypothetical protein (134063540)         0.698313           tyrosine aminotransferase         0.81461           conserved hypothetical protein (134063540)         0.68838           tyrosine aminotransferase         0.81461           conserved hypothetical protein (134063540)         0.81463           tyrosine aminotransferase         0.81461           Acytransferase         0.81		tryparedoxin_peroxidase	0.993897
putative signatodime krypanotikine synthetises 0.089999 provide signatodime in the synthetises 0.0649122 Phenylelanine metabolism PFLs-like, methyltransferase 1.287025 putative served hypothetical protein (134063540) 0.088384 byrosine aminotransferase 0.0677377 byrosine aminotransferase 0.0677377 provide sugar unit biosynthesis FLs-like, methyltransferase 0.0677377 provide sugar unit biosynthesis FLs-like, methyltransferase, type III 0.01692 putative served hypothetical protein (134063540) 0.08638 putative aminotransferase 0.081742 putative served hypothetical protein (134063540) 0.08638 putative served hypothetical protein (134063540) 0.08638 putative aspirates aminotransferase 0.081742 putative served hypothetical protein (134063540) 0.08638 putative served hypothetical protein (134063540) 0.08638 putative aspirates aminotransferase 0.081742 putative served hypothetical protein (134063540) 0.08638 putative aspirate aminotransferase 0.081742 putative aspirate aminotransferase 0.081742 putative aspirate aminotransferase 0.081742 putative aspirate aminotransferase 0.081748 putative aspirate aminotransferase 0.082537 formata = tetrahydrolatis glasso timplates 0.082537 putative served hydrogenase 1.1.1499 glycosomal malate dehydrogenase 1.1.1499 putative short chain 3-hydroxycyl-CoA dehydrogenase 0.082537 methylcrotonyl-coa carboxylase biotinylated subunityrotein-like protein 0.08254 eronyl-CoA hydratase/isomerase family protein,conserved 0.082537 methylcrotonyl-coa carboxylase biotinylated subunityrotein-like protein 0.08254 eronyl-CoA hydratase/isomerase family protein,conserved 0.082537 methylcrotonyl-coa carboxylase biotinylated subunityro		thiol-dependent_reductase_1	0.708709
Phenylalaniae metabolism ULBM glutanedoxim-like protein 0.0414/122 Phenylalaniae metabolism 0.1287025 putative sterol 24-c-methyltransferase 0.0479376 putative aspartate aminotransferase 0.041412 conserved hypothetical protein (134063345) 0.058831 putative aspartate aminotransferase 0.128703 putative arginine N-methyltransferase 0.041461 conserved hypothetical protein (134063540) 0.68638 putative arginine N-methyltransferase 0.041461 0.041456 putative arginine N-methyltransferase 0.041461 Acyltransferase 0.041463 DOWNREGULATED PROTEINS Tetrosine mitochondrial malate dehydrogenase 1.1.1499 glycosomal malate dehydrogenase 1.041492 Autive C-1-41ethydrofoldat sjutnase,choplasmic 0.06224 formate- =tethydrogenase family protein,conserved 0.06224 Valine, lauche and isoleucine degradation pathweys in prokanyotes methylcrononyl-coa carboxylase biolinylated subunitprotein-like protein 0.06224 Mitochondrial DNA topoisomerase I 0.06024 Valine, lauche and isoleucine degradation 0.062264 methylcrotonoyl-coa carboxylase biolinylated subunitprotein-like protein 0.062264 methylcrotonoyl-coa carboxylase biolinylated subunitprotein-like protein 0.062264 Mitochondrial DNA topoisomerase I 0.06024 Acyltransferase/Inconserved 0.062254 methylcrotonoy		putative trypanothione synthetase	0.689969
Phenylatanie metabolism PEs-Jike, methyltransferase 128/025 putative sterol 24-c-methyltransferase 0814614 conserved hypothetical protein (134063540) 088834 byrosine aminotransferase 0877561 conserved hypothetical protein (134063845) 057871 conserved hypothetical protein (134063845) 058703 putative sterol 24-c-methyltransferase 081461 putative anosterol synthase 081461 putative anosterol synthase 081126 putative sterol 24-c-methyltransferase 081126 putative sterol 24-c-methyltransferase 081126 putative lanosterol synthase 081126 putative lanosterol synthase 081126 putative lanosterol synthase 081126 putative sterol 24-c-methyltransferase 08126 putative lanosterol synthase 08126 putative sterol 24-c-methyltransferase 08126 putative lanosterol synthase 081276 putative lanosterol synthase 081276 putative lanosterol synthase 081276 putative lanosterol synthase 081918 methylorcolongi-coa carboxylase biotinylated subunitprotein-like protein 082837 formate -letnahydrolotal synthase.otyolasmic 08024 putative short chain 3-hydroxysol-coa dehydrogenase 10.06024 mitochondrial DNA topoisomerase II 0.06024 putative short chain 3-hydroxysol-coA dehydrogenase 10.06024 putative short chain 3-hydroxysol-coA dehydrogenase 10.06025 aldehyde dehydrogenase, mitochondrial precursor 0.		putative glutaredoxin-like protein	0.649122
Conserved hypothetical protein (134063540)         0.080344           Polyketide sugar unt biosynthesis         0.677376           Polyketide sugar unt biosynthesis         0.627521           Conserved hypothetical protein (134063540)         0.598311           Polyketide sugar unt biosynthesis         0.52752           Conserved hypothetical protein (134063540)         0.598311           Polyketide sugar unt biosynthesis         0.52752           Optative arginine N-methyltransferase         0.81461           Optative arginine N-methyltransferase, type III         0.61682           Uptative arginine N-methyltransferase         0.81461           Optative ANDP-dependent acorbid dehydrogenase         0.69638           Optative ANDP-dependent acorbid dehydrogenase         0.62762           Optative arginine N-methyltransferase, type III         0.81682	Phenylalanine metabolism	FtsJ-like_methyltransferase	1.287025
Conserved hypothetical protein (134005340) Ueb8384 putative asparatia a minotransferase 0.67376 Conserved hypothetical protein (134063845) Conserved hypothetical protein (134063845) Conserved hypothetical protein (134063845) Deb838 putative sterol 24-c-methyltransferase 0.81461 Conserved hypothetical protein (134063540) De2752 putative sterol 24-c-methyltransferase 0.81461 Conserved hypothetical protein (134063540) De2752 putative sterol 24-c-methyltransferase 0.81461 Apyltaneticalserase 0.81468 putative sterol 24-c-methyltransferase 0.81468 Apyltaneticalserase 0.81468 De2752 Dutative sterol 24-c-methyltransferase 0.81468 Apyltaneticalserase 0.81468 De2752 Dutative sterol 24-c-methyltransferase 0.81468 Apyltaneticalserase 0.81468 Apyltaneticalserase 0.81468 De2752 Dutative sterol 24-c-methyltransferase 0.81468 Apyltaneticalserase 0.81468 De18458		putative sterol 24-c-methyltransferase	0.814614
Durative asparate animotransferase         0.67567           Vorsine animotransferase         0.627567           Conserved hypothetical protein (134063549)         0.589311           Polytetide sugar unit biosynthesis         Ptal-like, methyltransferase         0.81461           Conserved hypothetical protein (134063540)         0.688381           putative arginine N-methyltransferase         0.81461           putative arginine N-methyltransferase, type III         0.61692           putative arginine N-methyltransferase         0.81461           Acyltransferase		conserved hypothetical protein (134063540)	0.686384
Voisine aminiotransferase         0.827621           Polyketide sugar unit biosynthesis         Fts-J-like_methyltransferase         0.81461           conserved hypothetical protein (134063540)         0.88831           putative seroi 24-c-methyltransferase         0.82762           putative arginine N-methyltransferase, type III         0.61692           putative arginine N-methyltransferase         0.82762           putative seroi 24-c-methyltransferase         0.81461           Acytransferase         0.81465           Tyrosine metabolism         Fts-J-like_methyltransferase         0.81465           Vorsine aminotransferase         0.81465         0.81465           putative stori 24-c-methyltransferase         0.81461           Acytransferase         0.69938         0.69938           putative NADP-dependent alcohd dehydrogenase         0.67933           putative anginine N-methyltransferase, type III         0.81692           DOWNREGULATED PROTEINS         mitochondrial malate dehydrogenase         -0.84038           carbon fixation pathways in prokaryotes         mitochondrial malate dehydrogenase         -0.82377           formate-teransfordolate ligate synthase, cytoplasmic         -0.86285         -0.82377           Valine, leucine and isoleucine degradation         methylicrotonaylase biotinylated subunitprotein-like protein </td <td></td> <td>putative aspartate aminotransferase</td> <td>0.679376</td>		putative aspartate aminotransferase	0.679376
Polyletide sugar unit biosynthesis (1492) Polyletide sugar unit biosynthesis (1492) Polyletide sugar unit biosynthesis (1492) putative sterol 24methyltransferase (0,883) tyrosine aminotransferase (0,883) tyrosine aminotransferase (0,883) tyrosine aminotransferase (0,883) tyrosine aminotransferase (0,883) tyrosine metabolism (1400) Pitabi-like_methyltransferase, type III (0,883) putative anosterol synthase (0,814) putative storol 24methyltransferase (0,814) putative NADP-dependent alcohol dehydrogenase (0,814) putative NADP-dependent alcohol dehydrogenase (0,878) putative anosterol synthase (0,878) putative anosterol synthase (0,814) DOWNREGULATED PROTEINS (1400) Carbon fixation pathways in prokaryotes (1,149) glycosomal malate dehydrogenase (0,414) formate-letrahydrolotale synthase (0,414) formate-letrahydrolotale synthase (0,414) formate-letrahydrolotale synthase (0,414) putative c1-iterahydrolotale synthase (0,414) encoh-drail DNA topoisomerase II (0,400) putative c1-iterahydrolotale synthase (0,414) encoh-draid DNA topoisomerase II (0,400) putative short chain 3-hydroxyacyl-CoA dehydrogenase (0,428) encoh-CoA hydratase/isomerase family protein,conserved (0,6284) methydrotonoyl-coa carboxylase biotinylated subunitprotein-like protein (0,6828) encoh-CoA hydratase/isomerase family protein,conserved (0,6284) mitchondrial DNA topoisomerase II (0,60294) dehydrogenase, mitchondrial precursor (0,6828) encoh-CoA hydratase/isomerase family protein,conserved (0,62284) mitchondrial DNA topoisomerase II (0,60294) dehydrogenase II (0,60294) d		tyrosine aminotransferase	0.627521
Polykelide sugar unit biosynthesis PEJ-like, methyltransferase 1,24703 Putative sterol 24-c-methyltransferase 0,81461 0,68638 0,62752 putative arginine N-methyltransferase, type III 0,61692 putative arginine N-methyltransferase, type III 0,61692 putative arginine N-methyltransferase 0,81461 0,6182 0,91410 0,6182 0,91410 0,6182 0,91410 0,6182 0,91410 0,6182 0,91410 0,6182 0,91410 0,6182 0,9141 0,6182 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,914 0,91 0,91 0,91 0,91 0,91 0,91 0,91 0,91		conserved hypothetical protein (134063845)	0.598311
Putative sterol 24-c-methyltransferase     0.81461       conserved hypothetical protein (13063540)     0.68653       fyrosine aminotransferase     0.82752       putative lanosterol synthase     0.61455       Tyrosine metabolism     FLS-Like, methyltransferase, type III     0.61692       putative lanosterol synthase     0.81461       Acyltransferase     0.81461       Acyltransferase     0.81461       Acyltransferase     0.81461       Dutative sterol 24-c-methyltransferase     0.81638       putative sterol 24-c-methyltransferase     0.81762       putative aspartate aminotransferase     0.81762       putative aspartate aminotransferase     0.62752       putative arginne N-methyltransferase, type III     0.61662       putative arginne N-methyltransferase     0.82752       putative arginne N-methyltransferase     0.82752       putative arginne N-methyltransferase     0.62752       putative short chain 3-hydroxyacyl-CoA dehydrogenase     0.62637	Polyketide sugar unit biosynthesis	FtsJ-like_methyltransferase	1.28703
Conserved hypothetical protein (13406340) 0.06563 putative arginine N-methyltransferase, type II 0.061632 putative lanosterol synthase 0.061166 putative sterol 24-c-methyltransferase 0.061938 putative sterol 24-c-methyltransferase 0.061938 putative sterol 24-c-methyltransferase 0.061938 putative arginine N-methyltransferase 0.061938 putative short chain 3-hydroxyccyl-CoA dehydrogenase 0.08257 formatetetrahydrofolate ligase 0.08108 methylcrotolate synthase.cytoplasmic 0.06268 putative chain 3-hydroxyccyl-CoA dehydrogenase 0.082537 iomatetetrahydrofolate ligase 0.08285 putative short chain 3-hydroxyccyl-CoA dehydrogenase 0.082857 aldehydrogenase II 0.065468 methylcrotonyl-coa carboxylase biotinylated subunitprotein-like protein 0.082857 aldehydrogenase II 0.065468 enoyl-CoA hydratase/isomerase family protein,conserved 0.082857 aldehydrogenase II 0.065468 enoyl-CoA hydratase/isomerase II 0.0656468 enoyl-CoA hydratase/isomerase II 0.065468 enoyl-CoA hydratase/isomerase II 0		putative sterol 24-c-methyltransferase	0.81461
Value, location         0.02/12/2           putative arginine N-methyltransferase, type III         0.61662           putative lanosterol synthase         0.61466           putative lanosterol synthase         0.61466           putative sterol 24-0-methyltransferase         0.81126           Adyltransferase         0.81126           putative sterol 24-0-methyltransferase         0.6938           conserved hypothetical protein (134063540)         0.68638           putative arginine N-methyltransferase         0.67938           tyrosine aminotransferase         0.61466           putative arginine N-methyltransferase, type III         0.61662           putative arginine N-methyltransferase, type III         0.61466           DOWNREGULATED PROTEINS         mitochondrial malate dehydrogenase         -0.81267           Carbon fixation pathways in prokaryotes         mitochondrial malate dehydrogenase         -0.82537           formate - tetrahydrofolate ligase         -0.81918         -0.81918           putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.8285         -0.8285           putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.8285         -0.8285           putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.8285         -0.8285           putative short chain 3-hydroxyacyl-CoA de		conserved hypothetical protein (134063540)	0.68638
Tyrosine metabolism         0.61632           Tyrosine metabolism         FtsJ-like_methyltransferase, type III         0.616436           Tyrosine metabolism         FtsJ-like_methyltransferase         0.81461           Acyttransferase         0.81126         0.81461           Acyttransferase         0.69938         0.69938           putative sportate aminotransferase         0.67938         0.67938           putative apprate aminotransferase         0.67938         0.67938           putative apprate aminotransferase         0.61932         0.61456           DOWNREGULATED PROTEINS         mitochondrial malate dehydrogenase         -1.1499           glycosomal malate dehydrogenase         -0.94403         -0.94403           putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.82537         -0.68285           putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68285         -0.68285           putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68285         -0.68285           valine, leucine and isoleucine degradation         putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68285           valine, leucine and isoleucine degradation         putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68285           enoyl-CoA hydratase/isomerase family protein,conserved         -0.68285		tyrosine aminotransferase	0.62752
Tyrosine metabolism         0.6 1436           Tyrosine metabolism         FSJ-like_methytiransferase         0.81461           Acyltransferase         0.81461         0.81461           Acyltransferase         0.81126         0.81126           putative sterol 24-c-methyltransferase         0.8938         0.68938           conserved hypothetical protein (134063540)         0.68663         0.62752           putative aspartate aminotransferase         0.67938         0.62752           putative aspartate aminotransferase         0.61456         0.62752           putative aspartate aminotransferase         0.64456         0.62752           putative lanosterol synthase         0.61456         0.62752           DOWNREGULATED PROTEINS         mitochondrial malate dehydrogenase         -0.94403           glycosomal malate dehydrogenase         -0.82537         6/mate           formate - tetrahydrofolate ligase         -0.82637         -0.84403           methylerotonoyl-coa carboxylase biotinylated subunitprotein-like protein         -0.62284           witochondrial DNA topoisomerase II         -0.60924           Valine, leucine and isoleucine degradation         putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.82537           Benzoate degradation         putative short chain 3-hydroxyacyl-CoA dehydrogenase <td></td> <td>putative arginine N-methyltransferase, type III</td> <td>0.61692</td>		putative arginine N-methyltransferase, type III	0.61692
Tyrosine metrazolism       Fis3-inke_menuntitransierase       1.22003         putative stord 22-c-methyltransferase       0.81461         Acyltransferase       0.81126         putative NADP-dependent alcohol dehydrogenase       0.69381         conserved hypothetical protein (134063540)       0.68663         putative aspartate aminotransferase       0.677938         putative argnine N-methyltransferase, type III       0.61652         putative anosterol synthase       0.61456         DOWNREGULATED PROTEINS       mitochondrial malate dehydrogenase       -0.94403         glycosomal malate dehydrogenase       -0.82537         formate – tetrahydrofolate ligase       -0.8168         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.62244         mitochondrial DNA topoisomerase II       -0.60924         valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.6224       -0.6224         mitochondrial DNA topoisomerase II       -0.60924       -0.6224         putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284       -0.62284         mitochondrial DNA topoisomerase II       -0.60924       -0.62284       -0.62284       -0.62284       -0.62284<	Townships weather lines	putative lanosterol synthase	0.61456
Valine, leucine and isoleucine degradation Valine, leucine and isole	Tyrosine metabolism	rtsj-like_methyltransierase	0.81461
Value isoleucine degradation Value isoleucine			0.81401
bitality       0.009300         conserved hypothetical protein (134063540)       0.68633         putative aspartate aminotransferase       0.67938         tyrosine aminotransferase       0.62752         putative arginine N-methyltransferase, type III       0.61692         putative lanosterol synthase       0.61456         DOWNREGULATED PROTEINS       mitochondrial malate dehydrogenase       -0.94403         putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         formate – tetrahydrofolate ligase       -0.65284         putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62844         putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62845         putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62844         mitochondrial INA topoisomerase II       -0.60924         Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.60924       -0.62284         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.60924       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.609271         mitochondrial DNA topoi		Acyliransierase	0.60028
Valine, leucine and isoleucine degradation Valine, leucine degradation Putative short chain 3-hydroxyacyl-CoA dehydrogenase addehyde dehydrogenase nitochondrial protein,conserved o.62284 mitochondrial DNA topoisomerase II OA6825 OOEST Carbon fixation pathways in prokaryotes Putative short chain 3-hydroxyacyl-CoA dehydrogenase Putative short chain 3		putative NADE-dependent alcohol denydrogenase	0.09930
Value aspart asset       0.62752         putative arginine N-methyltransferase       0.62752         putative arginine N-methyltransferase, type III       0.61692         putative lanosterol synthase       0.61752         DOWNREGULATED PROTEINS       mitochondrial malate dehydrogenase       -1.1499         glycosomal malate dehydrogenase       -0.94403       -0.94403         putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         formate – tetrahydrofolate ligase       -0.8468         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.65248         valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.822537         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.822537         aldehyde dehydrogenase, mitochondrial precursor       -0.69271         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.822537         aldehyde dehydrogenase all       -0.60924         mitochondrial DNA topoisomerase li       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.822537         aldehyde dehydrogenase, m		putativo aspartato aminotransforaso	0.00030
Valine, leucine and isoleucine degradation putative short chain 3-hydroxyacyl-CoA dehydrogenase enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation putative short chain 3-hydroxyacyl-CoA dehydrogenase enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation putative short chain 3-hydroxyacyl-CoA dehydrogenase enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydratase/isomerase li leucine and isoleucine degradation entrylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein enoyl-CoA hydrat			0.07958
Description         0.01002           putative lanosterol synthase         0.01002           DOWNREGULATED PROTEINS         mitochondrial malate dehydrogenase         -1.1499           glycosomal malate dehydrogenase         -0.94403           putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.82537           formate – tetrahydrofolate ligase         -0.81918           methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein         -0.68285           putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68285           valine, leucine and isoleucine degradation         putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68281           Benzoate degradation         putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68281           Benzoate degradation         putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68281           Glyoxylate and dicarboxylate metabolism         putative short chain 3-hydroxyacyl-CoA dehydrogenase         -0.68285           Glyoxylate and dicarboxylate metabolism <td< td=""><td></td><td>nutative aminiou ansierase</td><td>0.61692</td></td<>		nutative aminiou ansierase	0.61692
DOWNREGULATED PROTEINS       0.011430         Carbon fixation pathways in prokaryotes       mitochondrial malate dehydrogenase       0.094403         glycosomal malate dehydrogenase       0.094403         formate – tetrahydrofolate ligase       0.082537         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       0.68285         putative short chain 3-hydroxyacyl-CoA dehydrogenase       0.082284         motochondrial DNA topoisomerase II       0.060924         Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       0.08285         enoyl-CoA hydratase/isomerase II       0.060924         Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       0.08285         enoyl-CoA hydratase/isomerase II       0.060924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       0.062284         mitochondrial DNA topoisomerase II       0.060924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       0.062284         mitochondrial DNA topoisomerase II       0.060924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       0.062284         Mitochondrial DNA topoisomerase II       0.060924       0.062924         Benzoate		putative langesterol synthese	0.61456
Carbon fixation pathways in prokaryotes mitochondrial malate dehydrogenase -1.1499 głycosomal malate dehydrogenase -0.94403 putative short chain 3-hydroxyacyl-CoA dehydrogenase -0.82537 formate tetrahydrofolate iigase -0.81918 methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein -0.68268 enoyl-CoA hydratase/isomerase family protein,conserved -0.62284 mitochondrial DNA topoisomerase II -0.68257 dehydrogenase -0.82537 methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein -0.68268 enoyl-CoA hydratase/isomerase II -0.60924 valine, leucine and isoleucine degradation putative short chain 3-hydroxyacyl-CoA dehydrogenase -0.82537 methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein -0.68285 enoyl-CoA hydratase/isomerase II	DOWNREGULATED PROTEINS	putative infosteror synthase	0.01400
Calcion instation planting of the protein function instance of the planting of	Carbon fixation pathways in prokaryotes	mitochondrial malate dehydrogenase	-1 1499
putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         formate – tetrahydrofolate ligase       -0.81918         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285         putative C-1-tetrahydrofolate synthase,cytoplasmic       -0.65468         enoyl-CoA hydratase/isomerase family protein,conserved       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.69971         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285         enoyl-CoA hydratase/isomerase II       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Glyoxylate and dicarboxylate metabolism       mitochondrial DNA topoisomerase II       -0.60924         Glyoxylate and dicarboxylate metabolism       mitochondrial DNA topoisomerase II       -0.60924         mitochondrial DNA topoisomerase II       -0.60924       -0.62284     <	Carbon invation participation protection	divcosomal malate dehydrogenase	-0.94403
formate – tetrahydrofolate ligase       -0.81918         formate – tetrahydrofolate ligase       -0.81918         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285         putative C-1-tetrahydrofolate synthase,cytoplasmic       -0.65468         enoyl-CoA hydratase/isomerase family protein,conserved       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.6924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.6924         Glyoxylate and dicarboxylate metabolism       mitochondrial DNA topoisomerase II       -0.60228         mitochondrial DNA topoisomerase family protein,conserved       -0.62284         mitochondrial DNA topoisomerase II       -0.60228		putative short chain 3-hydroxyacyl-CoA dehydrogenase	-0.82537
Image: Section of the analysis		formate—tetrahydrofolate ligase	-0.81918
interfactor       0.65468         putative C-1-tetrahydrofolate synthase,cytoplasmic       -0.65284         mitochondrial DNA topoisomerase II       -0.60924         Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.69571         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.62284         mitochondrial DNA topoisomerase II       -0.62284         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.62284         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.60924         Benzoate degradation		methylcrotonovi-coa carboxylase biotinvlated subunitprotein-like protein	-0.68285
Partial of the information of the i		putative C-1-tetrahydrofolate synthase cytoplasmic	-0.65468
mitochondrial DNA topoisomerase II-0.60924Valine, leucine and isoleucine degradationputative short chain 3-hydroxyacyl-CoA dehydrogenase-0.82537aldehyde dehydrogenase, mitochondrial precursor-0.609571methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.608285enoyl-CoA hydratase/isomerase family protein,conserved-0.60924Benzoate degradationputative short chain 3-hydroxyacyl-CoA dehydrogenase-0.60924Benzoate degradationputative short chain 3-hydroxyacyl-CoA dehydrogenase-0.82537aldehyde dehydrogenase, mitochondrial precursor-0.60924mitochondrial DNA topoisomerase II-0.60924Benzoate degradationputative short chain 3-hydroxyacyl-CoA dehydrogenase-0.82537aldehyde dehydrogenase, mitochondrial precursor-0.69571methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.68285enoyl-CoA hydratase/isomerase family protein,conserved-0.62284mitochondrial DNA topoisomerase II-0.60924Glyoxylate and dicarboxylate metabolismmitochondrial malate dehydrogenase-0.60924glycosomal malate dehydrogenase-0.94403methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.68285enoyl-CoA hydratase/isomerase II-0.60924mitochondrial malate dehydrogenase-0.94403mitochondrial malate dehydrogenase-0.94403methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.68285enoyl-CoA hydratase/isomerase II-0.68285enoyl-CoA hydratase/isomeras		enovl-CoA hydratase/isomerase family protein.conserved	-0.62284
Valine, leucine and isoleucine degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.69571         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.62284         enoyl-CoA hydratase/isomerase family protein,conserved       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.6924         mitochondrial DNA topoisomerase II       -0.60924         putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.69271         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285         enoyl-CoA hydratase/isomerase family protein,conserved       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Glyoxylate and dicarboxylate metabolism       mitochondrial malate dehydrogenase       -0.60924         mitochondrial malate dehydrogenase       -0.94403       -0.60924         mitochondrial malate dehydrogenase       -0.94403       -0.68		mitochondrial DNA topoisomerase II	-0.60924
aldehyde dehydrogenase, mitochondrial precursor       -0.69571         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.69281         enoyl-CoA hydratase/isomerase family protein,conserved       -0.60924         mitochondrial DNA topoisomerase II       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.69571         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.6924         glyoxylate and dicarboxylate metabolism       mitochondrial DNA topoisomerase II       -0.69271         Glyoxylate and dicarboxylate metabolism       mitochondrial precursor       -0.69271         mitochondrial DNA topoisomerase II       -0.60224       -0.62284         mitochondrial DNA topoisomerase II       -0.60224       -0.62284         Mitochondrial DNA topoisomerase II       -0.60224       -0.60224         Mitochondrial malate dehydrogenase       -0.60224       -0.60224         Mitochondrial malate dehydrogenase       -0.60924       -0.60924         Mitochondrial malate dehydrogenase       -0.94403       -0.64285         glycosomal malate dehydrogenase       -0.94403       -0.68285         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein	Valine, leucine and isoleucine degradation	putative short chain 3-hydroxyacyl-CoA dehydrogenase	-0.82537
methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285         enoyl-CoA hydratase/isomerase family protein,conserved       -0.60924         mitochondrial DNA topoisomerase II       -0.60924         Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.69271         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.62284         motochondrial DNA topoisomerase II       -0.69571         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.62284         motochondrial DNA topoisomerase II       -0.60924         Glyoxylate and dicarboxylate metabolism       mitochondrial DNA topoisomerase II       -0.60924         Glyoxylate and dicarboxylate metabolism       mitochondrial malate dehydrogenase       -0.94403         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285		aldehyde dehydrogenase, mitochondrial precursor	-0.69571
enoyl-CoA hydratase/isomerase family protein,conserved-0.62284mitochondrial DNA topoisomerase II-0.60924Benzoate degradationputative short chain 3-hydroxyacyl-CoA dehydrogenase-0.82537aldehyde dehydrogenase, mitochondrial precursor-0.69571methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.62284mitochondrial DNA topoisomerase II-0.60924methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.62284mitochondrial DNA topoisomerase family protein,conserved-0.60924Glyoxylate and dicarboxylate metabolismmitochondrial malate dehydrogenase-1.1499glycosomal malate dehydrogenase-0.94403methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.68285		methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein	-0.68285
mitochondrial DNA topoisomerase II-0.60924Benzoate degradationputative short chain 3-hydroxyacyl-CoA dehydrogenase-0.82537aldehyde dehydrogenase, mitochondrial precursor-0.69571methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.68285enoyl-CoA hydratase/isomerase family protein,conserved-0.60924mitochondrial DNA topoisomerase II-0.60924Glyoxylate and dicarboxylate metabolismmitochondrial malate dehydrogenase-1.1499glycosomal malate dehydrogenase-0.94403methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein-0.68285		enoyl-CoA hydratase/isomerase family protein,conserved	-0.62284
Benzoate degradation       putative short chain 3-hydroxyacyl-CoA dehydrogenase       -0.82537         aldehyde dehydrogenase, mitochondrial precursor       -0.69571         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.62284         enoyl-CoA hydratase/isomerase family protein,conserved       -0.60924         mitochondrial malate dehydrogenase       -1.1499         glycosomal malate dehydrogenase       -0.94403         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285		mitochondrial DNA topoisomerase II	-0.60924
aldehyde dehydrogenase, mitochondrial precursor       -0.69571         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.62284         enoyl-CoA hydratase/isomerase family protein,conserved       -0.60924         mitochondrial DNA topoisomerase II       -0.60924         glycosomal malate dehydrogenase       -1.1499         glycosomal malate dehydrogenase       -0.94403         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285	Benzoate degradation	putative short chain 3-hydroxyacyl-CoA dehydrogenase	-0.82537
methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285         enoyl-CoA hydratase/isomerase family protein,conserved       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Glyoxylate and dicarboxylate metabolism       mitochondrial malate dehydrogenase       -1.1499         glycosomal malate dehydrogenase       -0.94403       -0.68285         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285		aldehyde dehydrogenase, mitochondrial precursor	-0.69571
enoyl-CoA hydratase/isomerase family protein,conserved       -0.62284         mitochondrial DNA topoisomerase II       -0.60924         Glyoxylate and dicarboxylate metabolism       mitochondrial malate dehydrogenase       -1.1499         glycosomal malate dehydrogenase       -0.94403       -0.68285         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285		methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein	-0.68285
Mitochondrial DNA topoisomerase II       -0.60924         Glyoxylate and dicarboxylate metabolism       mitochondrial malate dehydrogenase       -1.1499         glycosomal malate dehydrogenase       -0.94403         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285		enoyl-CoA hydratase/isomerase family protein, conserved	-0.62284
Glyoxylate and dicarboxylate metabolism       mitochondrial malate dehydrogenase       -1.1499         glycosomal malate dehydrogenase       -0.94403         methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein       -0.68285		mitochondrial DNA topoisomerase II	-0.60924
glycosomal malate dehydrogenase -0.94403 methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein -0.68285	Glyoxylate and dicarboxylate metabolism	mitochondrial malate dehydrogenase	-1.1499
methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein -0.68285		glycosomal malate dehydrogenase	-0.94403
		methylcrotonoyl-coa carboxylase biotinylated subunitprotein-like protein	-0.68285
enoyl-CoA hydratase/isomerase family protein, conserved -0.62284		enoyl-CoA hydratase/isomerase family protein,conserved	-0.62284
mitochondrial DNA topoisomerase II -0.60924		mitochondrial DNA topoisomerase II	-0.60924
Geraniol degradation putative short chain 3-hydroxyacyl-CoA dehydrogenase -0.82537	Geraniol degradation	putative short chain 3-hydroxyacyl-CoA dehydrogenase	-0.82537

#### TABLE 3 | Continued

PATHWAY	PROTEINS	RATIO(LbAL vs LbTL)
	aldehyde dehydrogenase, mitochondrial precursor	-0.69571
	enoyl-CoA hydratase/isomerase family protein, conserved	-0.62284
One carbon pool by folate	putative short chain 3-hydroxyacyl-CoA dehydrogenase	-0.82537
	aldehyde dehydrogenase, mitochondrial precursor	-0.69571
	enoyl-CoA hydratase/isomerase family protein, conserved	-0.62284

In bold proteins that are in more than one pathway, proteins sorted by log2-ratio.



phosphorylated proteins, which are associated with diverse cellular functions, including glycolysis, motility, mitosis, apoptosis, cell cycle progression, and signal transduction (Qureshi et al., 2019).

A clustering of several ribosomal proteins interacting with each other was observed with BP enrichment of 12 (from 27) ribosomal proteins, of which 9 interact with each other and all of which are positively regulated in strains from atypical lesions. Eukaryotic ribosomes have approximately 70 proteins, 30 of which are present in the smaller sub-unit and 40 in the larger sub-unit (Tsurugi et al., 1978), therefore, suggesting that 12 regulated proteins may not be related to increased ribosomal activity; however, in *Leishmania* spp., ribosome-related proteins have been considered relevant molecules during infection and have been shown to modulate cellular activity and cytokine release (Cordeiro-Da-Silva et al., 2001). Therefore, they are good candidates for vaccination (Iborra et al., 2008; Brito et al., 2017). These ribosomal proteins could be associated with immune response modulation, favorable to the parasites from atypical strains which the disease duration was significantly longer among ACL individual as reported in Guimarães et al. (2016).

Our results also demonstrate negative regulation of the oxidoreductase activity, acting on CH-OH group of donors, as well as acting on a sulfur group of donors, disulfide as an acceptor, groups represented mainly by malate dehydrogenase and choline dehydrogenase in atypical strains compared to typical strains. In this case, the higher negative ratios were malate dehydrogenase (-1.15) and choline dehydrogenase (-1.06). Furthermore, these categories included several downregulated dehydrogenases (malate dehydrogenase, choline dehydrogenase, dehydrogenase-like protein, short chain 3-hydroxyacyl-CoA dehydrogenase, and aldehyde dehydrogenase) that interact with each other (Figure 3). Dehydrogenases are oxidoreductase enzymes that catalyze the transfer of hydrogen and a pair of electrons from a reduced substrate, which is oxidized in the reaction, to an electronreceiving molecule, which in turn, is reduced. In higher eukaryotes, mitochondrial MDH (mMDH) is involved in the



capacity (50µM) and, thus, no standard deviation can be calculated.

transfer of reducing equivalents from the cytosol to the mitochondria, which is essential for the activity of the glycolytic pathway in the cytosol. MDH has been demonstrated in Leishmania over 20 years ago (Mottram and Coombs, 1985), although the metabolic roles of MDH isozymes in trypanosomatides have not yet been clearly established. Leroux et al. (2006) demonstrated the presence of three MDH isoforms with slightly distinct biochemical properties and different subcellular localizations (mitochondrial and cytosolic) in Leishmania spp., and verified that these isozymes are remarkably more abundant in amastigotes than in promastigotes of L. mexicana. These authors presumed that the functional and biochemical features of these isozymes reflect the metabolic adaptation to the different nutrient sources that these parasites have to face during their life cycle. In L. braziliensis, MDH was inferred from homology; however, consistent with the present work, de Rezende et al. (2017) found MDH in L. amazonensis. Similarly, the presence of choline dehydrogenase in Leishmania spp. was inferred from homology. Thus, to date, no reports are available for experimental activity data involving malate dehydrogenase and choline dehydrogenase in Leishmania spp., and it is possible to speculate the role of these enzymes in relation to the strains studied in the present work.

Another negative regulation observed in atypical strains was related to serine/threonine kinase activity by the putative target proteins of rapamycin (TOR) and kinase 1 protein kinase. Initially, TORs were identified by mutations that confer resistance to a potent antifungal metabolite called rapamycin (Heitman et al., 1991). TOR kinases are key master regulators in eukaryotes, linking environmental conditions, such as nutrient availability and stimuli, to protein synthesis and cell cycle machinery in order to coordinate cell growth and replication. *Leishmania* TOR mutants were unable to survive or replicate in macrophages *in vitro* or to induce pathology or establish infections in mice in vivo. The loss of virulence is associated with a defect in acidocalcisome formation, a unique organelle of protozoans that plays an important role in energy metabolism (Madeira da Silva and Beverley, 2010). Based on these data, the downregulation of TOR in atypical strains could confer less virulence to this strain compared to typical strains; however, only one protein is not sufficient to determine virulence. Thus, we cannot infer the role of regulation of this protein in the strains studied. Similarly, the downregulation of kinase 1 protein alone is very difficult to speculate because it belongs to an important family of proteins. A number of studies have explored the role of individual Leishmania protein kinases in promastigote survival, metacyclic differentiation, and amastigote replication, as well as their role in infectivity. Baker et al. (2021) identified regulators of differentiation or survival in a systematic functional analysis of Leishmania protein kinases. They applied kinome-wide gene deletion and gene tagging in L. mexicana promastigotes to define protein kinases with life cycle transition roles. While 162 are dispensable, 44 protein kinase genes are refractory to deletion in promastigotes and are likely core genes required for parasite replication. Therefore, to understand the role of this molecular function and its downregulated proteins, further studies are needed on the strains used in the present work.

The results presented here show that promastigotes from *L. braziliensis* strains isolated from atypical and typical lesions have proteins with different abundances. The comparison between these strains enabled the reproducible identification of several proteins that distinguish the two groups. Strains isolated from atypical forms showed an upregulation of proteins which may confer greater survival inside macrophages, proteins that influence the early stages of infection of the mammalian host (ISP), and proteins associated with resistance to antimony therapy. Moreover, peroxidase activity was 3.01-fold higher in the atypical strains than in the typical strains.

## DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ebi.ac. uk/pride/archive/, PXD029995.

### AUTHOR CONTRIBUTIONS

BE: Data Curation, formal analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation. MM-B: conceptualization, Methodology, Supervision, Writing – Review & Editing. VG: Methodology, Writing – Review & Editing TV-B: conceptualization, Methodology, Writing – Review & Editing. ML: conceptualization, Methodology, Writing – Review & Editing. CG: conceptualization, Writing – Review & Editing. PQ: conceptualization, Methodology, Writing – Review & Editing. HA: conceptualization, funding acquisition, Methodology, Project administration, resources, Supervision, Writing – Review & Editing. All authors contributed to the article and approved the submitted version.

# FUNDING

This research was supported by the Fundação de Amparo à Pesquisa do Estado de Minas Gerais [PPM00129-17], Instituto Nacional de Ciência e Tecnologia de Vacinas [CNPq-573547/2008-4/FAPEMIG/MS-CBB, APQ 00077-09] and Rede Mineira de Biomoléculas [CCBRED00012-14]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. HA is CNPq fellows (PQ). BE and MM-B are CAPES fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

# REFERENCES

- Alam, M. N., Das, P., De, T., and Chakraborti, T. (2016). Identification and Characterization of a Leishmania Donovani Serine Protease Inhibitor: Possible Role in Regulation of Host Serine Proteases. *Life Sci.* 144, 218–225. doi: 10.1016/j.lfs.2015.12.004
- Andrade, J. M., and Murta, S. M. (2014). Functional Analysis of Cytosolic Tryparedoxin Peroxidase in Antimony-Resistant and -Susceptible Leishmania Braziliensis and Leishmania Infantum Lines. *Parasit. Vectors* 7, 406. doi: 10.1186/1756-3305-7-406
- Baker, N., Catta-Preta, C. M. C., Neish, R., Sadlova, J., Powell, B., Alves-Ferreira, E. V. C., et al. (2021). Systematic Functional Analysis of Leishmania Protein Kinases Identifies Regulators of Differentiation or Survival. *Nat. Commun.* 12 (1), 1244. doi: 10.1038/s41467-021-21360-8
- Baptista, C., Schubach, A. O., Madeira, M. F., Leal, C. A., Pires, M. Q., Oliveira, F. S., et al. (2009). Leishmania (Viannia) Braziliensis Genotypes Identified in Lesions of Patients With Atypical or Typical Manifestations of Tegumentary Leishmaniasis: Evaluation by Two Molecular Markers. *Exp. Parasitol.* 121 (4), 317–322. doi: 10.1016/j.exppara.2008.12.006
- Brito, R. C., Guimarães, F. G., Velloso, J. P., Corrêa-Oliveira, R., Rui, J. C., Reis, A. B., et al. (2017). Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and *In Silico* Studies. *Int. J. Mol. Sci.* 18 (2), 371. doi: 10.3390/ijms18020371
- Calvopina, M., Gomez, E. A., Uezato, H., Kato, H., Nonaka, S., and Hashiguchi, Y. (2005). Atypical Clinical Variants in New World Cutaneous Leishmaniasis: Disseminated, Erysipeloid, and Recidiva Cutis Due to Leishmania (V.) Panamensis. Am. J. Trop. Med. Hyg 73 (2), 281–284. doi: 10.4269/ajtmh. 2005.73.281
- Colotti, G., Baiocco, P., Fiorillo, A., Boffi, A., Poser, E., Chiaro, F. D., et al. (2013). Structural Insights Into the Enzymes of the Trypanothione Pathway: Targets for Antileishmaniasis Drugs. *Future Med. Chem.* 5, 1861–1875. doi: 10.4155/ fmc.13.146
- Cordeiro-Da-Silva, A., Borges, M. C., Guilvard, E., and Ouaissi, A. (2001). Dual Role of the Leishmania Major Ribosomal Protein S3a Homologue in Regulation of T- and B-Cell Activation. *Infect. Immun.* 69 (11), 6588–6596. doi: 10.1128/IAI.69.11.6588-6596.2001
- Costa-Silva, M. F., Gomes, L. I., Martins-Filho, O. A., Rodrigues-Silva, R., de Moura Freire, J., Quaresma, P. F., et al. (2014). Gene Expression Profile of Cytokines and Chemokines in Skin Lesions From Brazilian Indians With Localized Cutaneous Leishmaniasis. *Mol. Immunol.* 57 (2), 74–85. doi: 10.1016/j.molimm.2013.08.008
- Cupolillo, E., Grimaldi, G Jr, and Momen, H. (1994). A General Classification of New World Leishmania Using Numerical Zymotaxonomy. Am. J. Trop. Med. Hyg. 50 (3), 296–311. doi: 10.4269/ajtmh.1994.50.296

# ACKNOWLEDGMENTS

We also would like to thank Editage (www.editage.com) for English language editing.

# SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.824968/full#supplementary-material

Supplementary Table S1 | All proteins identified by MS/MS.

Supplementary Table S2 | Proteins identified by MS/MS in each run with abundance increased in Atypical (LbAL) strains compared to Typical (LbTL) strains.

Supplementary Table S3 | Proteins identified by MS/MS in each run with abundance decreased in Atypical (LbAL) strains compared to Typical (LbTL) strains.

- Da-Cruz, A. M., Filgueiras, D. V., Coutinho, Z., Mayrink, W., Grimaldi, G.Jr., De Luca, P. M., et al. (1999). Atypical Mucocutaneous Leishmaniasis Caused by Leishmania Braziliensis in an Acquired Immunodeficiency Syndrome Patient: T-Cell Responses and Remission of Lesions Associated With Antigen Immunotherapy. *Mem Inst Oswaldo Cruz*; 94 (4), 537–542. doi: 10.1590/ S0074-02761999000400020
- Davidson, R. N. (1999). Visceral Leishmaniasis in Clinical Practice. J. Infect. 39 (2), 112–116. doi: 10.1016/s0163-4453(99)90001-4
- de Rezende, E., Kawahara, R., Peña, M. S., Palmisano, G., and Stolf, B. S. (2017). Quantitative Proteomic Analysis of Amastigotes From Leishmania (L.) amazonensis LV79 and PH8 Strains Reveals Molecular Traits Associated With the Virulence Phenotype. *PLoS Negl. Trop. Dis.* 11 (11), e0006090. doi: 10.1371/journal.pntd.0006090
- Eschenlauer, S. C., Faria, M. S., Morrison, L. S., Bland, N., Ribeiro-Gomes, F. L., DosReis, G. A., et al. (2009). Influence of Parasite Encoded Inhibitors of Serine Peptidases in Early Infection of Macrophages With Leishmania Major. *Cell. Microbiol.* 11 (1), 106–120. doi: 10.1111/j.1462-5822.2008.01243.x
- Fialho Junior, L., da Fonseca Pires, S., Burchmore, R., McGill, S., Weidt, S., Ruiz, J. C., et al. (2021). Proteomic Analysis Reveals Differentially Abundant Proteins Probably Involved in the Virulence of Amastigote and Promastigote Forms of Leishmania Infantum. *Parasitol. Res.* 120, 679–692. doi: 10.1007/s00436-020-07020-8
- Guimarães, L. H., Machado, P. R., Lago, E. L., Morgan, D. J., Schriefer, A., Bacellar, O., et al. (2009). Atypical Manifestations of Tegumentary Leishmaniasis in a Transmission Area of Leishmania Braziliensis in the State of Bahia, Brazil. *Trans. R. Soc. Trop. Med. Hygiene* 103 (7), 712–715. doi: 10.1016/ j.trstmh.2009.04.019
- Guimarães, L. H., Queiroz, A., Silva, J. A., Silva, S. C., Magalhães, V., Lago, E. L., et al. (2016). Atypical Manifestations of Cutaneous Leishmaniasis in a Region Endemic for Leishmania Braziliensis: Clinical, Immunological and Parasitological Aspects. *PloS Negl Trop. Dis.* 10 (12), e0005100. doi: 10.1371/ journal.pntd.0005100
- Heitman, J., Movva, N. R., and Hall, M. N. (1991). Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast. *Sci.* 253 (5022), 905–909. doi: 10.1126/science.1715094
- Iborra, S., Parody, N., Abánades, D. R., Bonay, P., Prates, D., Novais, F. O., et al. (2008). Vaccination With the Leishmania Major Ribosomal Proteins Plus Cpg Oligodeoxynucleotides Induces Protection Against Experimental Cutaneous Leishmaniasis in Mice. *Microbes Infect.* 10 (10-11), 1133–1141. doi: 10.1016/ j.micinf.2008.06.002
- Iftikhar, N., Bari, I., and Ejaz, A. (2003). Rare Variants of Cutaneous Leishmaniasis: Whitlow, Paronychia, and Sporotrichoid. Int. J. Dermatol. 42 (10), 807–809. doi: 10.1046/j.1365-4362.2003.02015.x
- Jiang, Q., Yan, Y., Hu, G., and Zhang, Y. (2005). Molecular Cloning and Characterization of a Peroxiredoxin From Phanerochaete Chrysosporium. *Cell Mol. Biol. Lett.* 10, 659–668.

- Karincaoglu, Y., Esrefoglu, M., and Ozcan, H. (2004). Atypical Clinical Form of Cutaneous Leishmaniasis: Erysipeloid Form. Int. J. Dermatol. 43 (11), 827–829. doi: 10.1111/j.1365-4632.2004.02324.x
- Lainson, R., and Shaw, J. J. (1998). "New World Leishmaniasis Neotropical Leishmania Species" In: Cox, FE, Kreier, JP, and Wakelin, D, editors. *Topley & Wilson's Microbiology and Microbial Infections. 9th ed.* London: Hodder Headline Group. p. 241–266.
- Leroux, A., Fleming-Canepa, X., Aranda, A., Maugeri, D., Cazzulo, J. J., Sánchez, M. A., et al. (2006). Functional Characterization and Subcellular Localization of the Three Malate Dehydrogenase Isozymes in Leishmania Spp. *Mol. Biochem. Parasitol* 149 (1), 74–85. doi: 10.1016/j.molbiopara.2006.04.010
- Madeira da Silva, L., and Beverley, S. M. (2010). Expansion of the Target of Rapamycin(TOR) Kinase Family and Function in Leishmania Shows That TOR3 is Required for Acidocalcisome Biogenesis and Animal Infectivity. Proc. Natl. Acad. Sci. U.S.A. 107 (26), 11965–11970. doi: 10.1073/pnas.1004599107
- Mittal, M. K., Misra, S., Owais, M., and Goyal, N. (2005). Expression, Purification, and Characterization of Leishmania Donovani Trypanothione Reductase in Escherichia Coli. Protein Expr. Purif. 40 (2), 279–286. doi: 10.1016/j.pep.2004.12.012
- Moreira, D. S., and Murta, S. M. (2016). Involvement of Nucleoside Diphosphate Kinase B and Elongation Factor 2 in Leishmania Braziliensis Antimony Resistance Phenotype. *Parasit. Vectors* 9 (1), 641. doi: 10.1186/s13071-016-1930-6
- Motram, C., and Coombs, G. H. (1985). Purification of Particulate Malate Dehydrogenase and Phosphoenol Pyruvate Carboxykinase From Leishmania Mexicana Mexicana. *Biochem. Biophys. Acta* 827 pp, 310–319. doi: 10.1016/ 0167-4838(85)90216-x
- Nagy, Z. A., Szakács, D., Boros, E., Héja, D., Vígh, E., Sándor, N., et al. (2019). Ecotin, a Microbial Inhibitor of Serine Proteases, Blocks Multiple Complement Dependent and Independent Microbicidal Activities of Human Serum. *PloS Pathog.* 15 (12), e1008232. doi: 10.1371/journal.ppat.1008232
- Negrão, F., Diedrich, J. K., Giorgio, S., Eberlin, M. N., and Yates, J. R.3rd. (2019). Tandem Mass Tag Proteomic Analysis of *In Vitro* and *In Vivo* Models of Cutaneous Leishmaniasis Reveals Parasite-Specific and Nonspecific Modulation of Proteins in the Host. ACS Infect. Dis. 5 (12), 2136–2147. doi: 10.1021/acsinfecdis.9b00275
- Omidian, M., and Mapar, M. A. (2006). Chronic Zosteriform Cutaneous Leishmaniasis. Indian J. Dermatol. Venereol. Leprol. 72 (1), 41-42. doi: 10.4103/0378-6323.19717
- Patino, L. H., Imamura, H., Cruz-Saavedra, L., Pavia, P., Muskus, C., Mendez, C., et al. (2019a). Major Changes in Chromosomal Somy, Gene Expression and Gene Dosage Driven by Sb(III) in Leishmania Braziliensis and Leishmania Panamensis. *Sci. Rep.* 9, 9485. doi: 10.1038/s41598-019-45538-9
- Pawar, H., Sathe, G., and Patole, M. S. (2020). Genome-Wide Proteomics and Phosphoproteomics Analysis of Leishmania Spp. During Differentiation. *Methods Mol. Biol.* 2116, 161–176. doi: 10.1007/978-1-0716-0294-2\_12
- Polpitiya, A. D., Wei-Jun, Q., Navdeep, J., Vladislav, A. P., Joshua, N. A., David, G. C.II, et al. (2008). Dante: A Statistical Tool for Quantitative Analysis of -Omics Data. *Bioinf.* 24 (13), 1556–1558. doi: 10.1093/bioinformatics/btn217
- Quaresma, P. F., de Brito, C. F. A., Rugani, J. M. N., Freire, J. M., Baptista, R. P., Moreno, E. C., et al. (2018). Distinct Genetic Profiles of Leishmania (Viannia)

Braziliensis Associate With Clinical Variations in Cutaneous-Leishmaniasis Patients From an Endemic Area in Brazil. *Parasitology* 145 (9), 1161–1169. doi: 10.1017/S0031182018000276

- Qureshi, R., Jakkula, P., Sagurthi, S. R., and Qureshi, I. A. (2019). Protein Phosphatase 1 of Leishmania Donovani Exhibits Conserved Catalytic Residues and Pro-Inflammatory Response. *Biochem. Biophys. Res. Commun.* 516 (3), 770–776. doi: 10.1016/j.bbrc.2019.06.085
- Rego, F. D., Da Rocha Lima, A., Pereira, A. A. S., Quaresma, P. F., Pascoal-Xavier, M. A., Shaw, J. J., et al. (2018). Genetic Variant Strains of Leishmania (Viannia) Braziliensis Exhibit Distinct Biological Behaviors. *Parasitol. Res.* 117, 3157– 3168. doi: 10.1007/s00436-018-6014-4
- Rodríguez-Veja, A., Losada-Barragán, M., Berbert, L. R., Mesquita-Rodrigues, C., Bombaça, A. C. S., Menna-Barreto, R., et al. (2021). Quantitative Analysis of Proteins Secreted by Leishmania (Viannia) Braziliensis Strains Associated to Distinct Clinical Manifestations of American Tegumentary Leishmaniasis. J. Proteomics 232, 104077. doi: 10.1016/j. jprot.2020.104077
- Rugani, J. N., Gontijo, C. M. F., Frézard, F., Soares, R. P., and Monte-Neto, R. L. D. (2019). Antimony Resistance in Leishmania (Viannia) Braziliensis Clinical Isolates From Atypical Lesions Associates With Increased ARM56/ARM58 Transcripts and Reduced Drug Uptake. *Mem. Inst Oswaldo Cruz* 114, e190111. doi: 10.1590/0074-02760190111
- Tsurugi, K., Collatz, E., Todokoro, K., Ulbrich, N., Lightfoot, H. N., and Wool, I. G. (1978). Isolation of Eukaryotic Ribosomal Proteins. Purification and Characterization of the 60 s Ribosomal Subunit Proteins La, Lb, Lf, P1, P2, L13', L14, L18', L20, and L38. J. Biol. Chem. 253 (3), 946–955. doi: 10.1016/ S0021-9258(17)38196-6
- Wyllie, S., Cunningham, M. L., and Fairlamb, A. H. (2004). Dual Action of Antimonial Drugs on Thiol, Redox Metabolism in the Human Pathogen Leishmania Donovani. J. Biol. Chem. 279, 39925–39932. doi: 10.1074/ jbc.M405635200

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Esteves, Melo-Braga, Gorshkov, Verano-Braga, Larsen, Gontijo, Quaresma and Andrade. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.